doripenem has been researched along with cilastatin in 8 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (12.50) | 29.6817 |
2010's | 7 (87.50) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Katsube, T; Yamano, Y; Yano, Y | 1 |
Chen, J; Mody, SH; Shorr, AF; Zilberberg, MD | 1 |
Bonomo, RA; Endimiani, A; Papp-Wallace, KM; Taracila, MA | 1 |
Chastre, J; Cirillo, I; Clavel, M; Kaniga, K; Kimko, H; Kollef, MH; Michiels, B; Redman, R; Restrepo, MI | 1 |
Kurtinecz, M; Li, G; Mitrani-Gold, FS; Mundy, LM; Singh, KP; Tomayko, JF; Wetherington, J | 1 |
Cannon, JP; Clark, NM; Grim, SA; Lee, TA; Setlak, P | 1 |
Igarashi, Y; Inui, K; Ohara, H; Ryozawa, S; Tazuma, S; Tsuyuguchi, T | 1 |
3 review(s) available for doripenem and cilastatin
Article | Year |
---|---|
Carbapenems: past, present, and future.
Topics: Anti-Bacterial Agents; beta-Alanine; beta-Lactams; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Doripenem; Drug Combinations; Ertapenem; Humans; Imipenem; Thienamycins | 2011 |
Systematic review and meta-analysis of antimicrobial treatment effect estimation in complicated urinary tract infection.
Topics: Anti-Bacterial Agents; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Clinical Trials as Topic; Databases, Bibliographic; Doripenem; Drug Combinations; Female; Humans; Imipenem; Levofloxacin; Male; Research Design; Treatment Outcome; Urinary Tract Infections | 2013 |
The risk of seizures among the carbapenems: a meta-analysis.
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Child; Cilastatin; Cilastatin, Imipenem Drug Combination; Doripenem; Drug Combinations; Ertapenem; Humans; Imipenem; Meropenem; Risk; Seizures; Thienamycins | 2014 |
2 trial(s) available for doripenem and cilastatin
Article | Year |
---|---|
A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Cilastatin; Doripenem; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Imipenem; Infusions, Intravenous; Male; Middle Aged; Pneumonia, Ventilator-Associated; Young Adult | 2012 |
Clinical efficacy of intravenous doripenem in patients with acute biliary tract infection: a multicenter, randomized, controlled trial with imipenem/cilastatin as comparator.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Body Temperature; C-Reactive Protein; Carbapenems; Cholangitis; Cholecystitis, Acute; Cilastatin; Cilastatin, Imipenem Drug Combination; Doripenem; Drug Combinations; Female; Humans; Imipenem; Infusions, Intravenous; Male; Middle Aged; Treatment Outcome; Young Adult | 2015 |
3 other study(ies) available for doripenem and cilastatin
Article | Year |
---|---|
Pharmacokinetic-pharmacodynamic modeling and simulation for in vivo bactericidal effect in murine infection model.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Bacterial Infections; Carbapenems; Cilastatin; Disease Models, Animal; Doripenem; Female; Imipenem; Meropenem; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Models, Biological; Thienamycins | 2008 |
Cost-effectiveness model of empiric doripenem compared with imipenem-cilastatin in ventilator-associated pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Cost-Benefit Analysis; Doripenem; Drug Combinations; Humans; Imipenem; Length of Stay; Middle Aged; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Quality-Adjusted Life Years; Young Adult | 2010 |
Doripenem: excess mortality.
Topics: Anti-Bacterial Agents; Carbapenems; Cilastatin; Cilastatin, Imipenem Drug Combination; Doripenem; Drug Combinations; Early Termination of Clinical Trials; Evidence-Based Medicine; Humans; Imipenem; Pneumonia, Ventilator-Associated; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome | 2012 |